CDX2 and malignant colon neoplasm: There is some evidence to suggest that (i) patients with CDX2-negative tumours have lower survival rates than those with CDX2-positive tumours and that (ii) the loss of CDX2 expression can identify a subset of patients with stage II colon cancer who are at high risk for disease recurrence and may benefit from adjuvant chemotherapy [20].